Jagsonpal Pharmaceuticals Ltd.: AGM on Sep 18, 2026; Record Date Sep 04 for Dividend
Jagsonpal Pharmaceuticals will hold its 47th AGM on September 18, 2026, via VC/OAVM. The company fixed September 04, 2026, as the record date for a recommended dividend of ₹4 per share (200%) for FY26, subject to shareholder approval.
The announcement concerns the AGM date and record date for dividend, which are important for shareholders but do not represent a significant change in the company's business operations or financial performance.
The announcement is a routine intimation regarding the AGM and record date for dividend payment, with no significant positive or negative financial news.
Jagsonpal Pharmaceuticals Limited announced that its 47th Annual General Meeting (AGM) will be held on Friday, September 18, 2026, at 03:30 p.m. IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM), in compliance with applicable circulars from the Ministry of Corporate Affairs and SEBI.
The Board of Directors, in their meeting on April 27, 2026, recommended a dividend of ₹4 per equity share (200%) for the financial year ended March 31, 2026. This dividend is subject to the approval of the shareholders at the upcoming AGM.
Furthermore, pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has fixed Friday, September 04, 2026, as the 'Record Date'. This date will be used to determine the entitlement of members to the proposed dividend for the financial year ended March 31, 2026. The dividend, if approved by the shareholders, will be paid within 30 days from its declaration, after deducting applicable taxes.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.